Perfusion Cell Culture Processes for Biopharmaceuticals

Moritz Wolf is a management consultant at McKinsey & Company and a former post-doctoral fellow at ETH Zurich in the department of Chemistry and Applied Biosciences. He has obtained the degree of Doctor of Science from ETH Zurich. Jean-Marc Bielser is an associate manager in the Biopharma Technology and Innovation group at Merck Serono SA (Switzerland). He obtained his master in Chemical Engineering and Biotechnology from EPFL, and the degree of Doctor of Science from ETH Zürich. Massimo Morbidelli is Professor Emeritus in the Department of Chemistry and Applied Biosciences at ETH Zurich and Professor at the Department of Chemistry, Materials and Chemical Engineering at the Politecnico di Milano. Member of the Italian Academy of Sciences (Accademia dei Lincei), he received the Excellence in Process Development Research Award in 2017 from the American Institute of Chemical Engineers, the 2018 Separations Science and Technology Award from the American Chemical Society and the 2019 Award in Integrated Continuous Biomanufacturing. He is the co-author of Continuous Biopharmaceutical Processes (Cambridge, 2018), and Parametric Sensitivity in Chemical Systems (Cambridge, 2005).

• 1. Perfusion mammalian cell culture for recombinant protein manufacturing; 2. Perfusion bioreactors; 3. Scale-down models and sensors for process development; 4. Design and optimization of mammalian cell perfusion cultures; 5. Clinical and commercial-scale reactors; 6. Mechanistic and statistical modeling of bioprocesses.

'Captures in a masterful way the many dimensions of perfusion cell culture technology, including its history, key concepts, relevant cell biology, hardware and instrumentation, mathematical modeling, and scale up technics, all supported by lucid examples that will resonate with the biotechnology professional. The book captures the cutting-edge advances in the field achieved only over the last few years, with a broad applicability to the manufacture of traditional molecular biotherapeutic, as well as complex new modalities, such as gene and cell therapies, and vaccines. Not surprisingly, the leading expertise of [this] team in continuous downstream operation is reflected in the introduction of a fully integrated continuous biomanufacturing platform, which has all the requisite qualities to become the dominant architectural design of the future.' Konstantin Konstantinov, Codiak BioSciences